Synairgen

Synairgen is a clinical-stage biotech focused on developing inhaled interferon beta (SNG001) as a broad-spectrum, host-directed antiviral for severe respiratory infections. Founded on pioneering academic research into lung immunology, the company has advanced SNG001 through multiple clinical trials, including during the COVID-19 pandemic, demonstrating proof-of-concept. Its current strategy is to target the high-mortality, underserved population of mechanically ventilated patients in intensive care through a Phase 2 trial (INVENT), leveraging a novel mechanism of action that is agnostic to the specific virus.

Platform centered on inhaled delivery of interferon-beta (IFN-β) to boost the lungs' innate immune defenses, based on pioneering ex vivo human lung model research identifying IFN-β deficiency as a key driver of severe viral illness.

Competes with virus-specific direct-acting antivirals but is a leader in developing a broad-spectrum, host-directed inhaled therapy for severe disease. Faces limited direct competition in the specific niche of inhaled IFN-β for the ICU, but larger players could enter the space.